FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely to a powder composition and a preparation based on it for the prevention and/or treatment of metabolic syndromes, dyslipidemia and type 2 diabetes. A method for the production of a solid powder composition includes following stages: a) dispersion of an aqueous-alcoholic extract of bergamot fruit in at least one polar proton or aprotic organic solvent selected from linear or branched C1-C8 alkyl alcohol, linear or branched C1-C8 alkyl ether and C1-C8 dialkyl ketone, and holding while mixing until a solution or a dispersion is obtained; heating is optional; in this case, the extract contains flavonoids neoeriocitrin, naringin and neohesperidin; b) then, addition of at least one phospholipid, sunflower lecithin, to the solution or the dispersion of the extract, and holding the mixture while mixing; optionally use of heating, where at least one phospholipid is sunflower lecithin; or a) dispersion of an aqueous-alcoholic extract of bergamot fruit, and b) at least one phospholipid in at least one polar proton or aprotic organic solvent selected from linear or branched C1-C8 alkyl alcohol, linear or branched C1-C8 alkyl ether and C1-C8 dialkyl ketone, and holding while mixing until a solution or a dispersion is obtained; optionally, use of heating; the extract contains flavonoids neoeriocitrin, naringin and neohesperidin, and at least one phospholipid is sunflower lecithin; where the mass ratio between at least one phospholipid and flavonoids of the extract varies from 6 to 30; optionally, use of heating; and c) then, removal of an organic solvent to obtain a solid powder composition. The solid powder composition for the prevention and/or treatment of metabolic syndromes, dyslipidemia and type 2 diabetes is obtained by the above-described production method. A pharmaceutical preparation for the prevention and/or treatment of metabolic syndrome, dyslipidemia and type 2 diabetes includes a solid powder composition and at least one physiologically acceptable excipient and/or carrier.
EFFECT: above-described composition and the preparation based on it are characterized by increased oral bioavailability of active ingredients, they are effective for the prevention and/or treatment of metabolic syndrome, dyslipidemia and type 2 diabetes.
11 cl, 2 tbl, 6 ex
